Skip to main content
Claritas Pharmaceuticals, Inc. logo

Claritas Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CLAZF ISIN · CA1806342061 LEI · 529900L41UFXOXZ1G169 TSXV Manufacturing
Open in API
Filings indexed 98 across all filing types
Latest filing 2022-07-22 Regulatory Filings
Country CA Canada
Listing TSXV CLAZF

About Claritas Pharmaceuticals, Inc.

https://claritaspharma.com/

Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products addressing areas of unmet medical need. The company maintains a portfolio of pharmaceutical candidates, with a primary focus on advancing its lead compound, R-107. R-107 is being developed as a potential therapy for various viral infections, including influenza and COVID-19. The company's development pipeline also explores treatments within therapeutic areas such as Nervous System Diseases.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Claritas Pharmaceuticals, Inc. MATERIAL CHANGE REPORT' and details a Failure-to-File Cease Trade Order (FFCTO) issued by the British Columbia Securities Commission due to the company's failure to file its annual financial statements and interim financial reports by the prescribed deadlines. The document includes a news release about the FFCTO, explanations for the failure to file, and the impact on trading suspension. It does not contain the actual financial statements or substantive financial data but rather announces regulatory actions and company status updates related to filings. The document is approximately 8,278 characters, which is relatively short and primarily serves as a regulatory announcement about material changes and filing failures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not contain full reports themselves.
2022-07-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the British Columbia Securities Commission (BCSC) has issued a Failure-to-File Cease Trade Order (FFCTO) against Claritas Pharmaceuticals due to the company's failure to file its annual financial statements for the year ending December 31, 2021, interim financial report for the period ended March 31, 2022, management's discussion and analysis for those periods, and certifications. The document explains the reasons for the failure to file, the impact on trading, and the company's plans to resolve the issue. It does not contain the actual financial statements or substantive financial data but is an announcement regarding regulatory action and filing status. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2022-07-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a corporate update regarding a management cease trade order (MCTO) issued by the British Columbia Securities Commission due to the company's failure to file its annual audited financial statements and related annual documents by the deadline. It discusses delays in filing the annual documents and interim quarterly filings, the reasons for these delays, and the company's plans to resolve the issues. The document is a status update and notification about regulatory compliance and filing delays rather than the actual annual report, interim report, or financial statements themselves. It also references National Policy Statement 12-203 and provides bi-weekly default status reports as required. The document does not contain actual financial data or the reports themselves but is an announcement about the filing status and regulatory compliance. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit into other specific categories.
2022-06-24 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Material Change Report filed by Claritas Pharmaceuticals, Inc. It discusses a management cease trade order (MCTO) issued by the British Columbia Securities Commission due to the company's anticipated inability to file its annual audited financial statements and related annual documents by the deadline. The document references the delay in filing the Annual Documents for the fiscal year ending December 31, 2021, and states the company expects to file these documents by June 30, 2022. The report includes a detailed explanation of the situation, regulatory references, and the impact on management trading. It is not the annual report itself, nor the financial statements, but rather a regulatory announcement about a material change related to the filing status and regulatory compliance. The document length is 9096 characters, which is substantial but the content is clearly an announcement of a material change and regulatory status rather than a full financial report or audit report. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement about compliance and filing status that does not contain the actual annual report or financial statements.
2022-05-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is an update regarding a Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission due to the company's failure to file its annual audited financial statements and related annual documents by the deadline. It provides a status report on the filing delay and compliance with National Policy Statement 12-203. The document does not contain the actual annual report or financial statements but is a regulatory update about the delay and the company's efforts to file the required documents. It is a bi-weekly status report related to regulatory compliance rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance updates that do not contain the actual financial reports.
2022-05-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a management cease trade order (MCTO) issued by the British Columbia Securities Commission due to the company's failure to file its annual audited financial statements and related annual documents by the deadline. It discusses the delay in filing the annual documents, the expected filing date, and the implications of the MCTO. The document does not contain the annual report or financial statements themselves but rather announces the filing default and regulatory action. It is a regulatory announcement about the status of filings and management trading restrictions, not the actual annual report or audit report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2022-05-05 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.